ELAN trades 3.6% below Wall Street's consensus target of $26.67.
Last 12 months price action with 12-month analyst target path
The base valuation assumes ELAN achieves its forward estimates and maintains a stable P/E multiple of 22.7x. This scenario reflects the blended consensus of 22 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 8, 2026, Elanco Animal Health Incorporated (ELAN) has a Wall Street consensus price target of $26.67, based on estimates from 22 covering analysts. With the stock currently trading at $25.74, this represents a potential upside of +3.6%. The company has a market capitalization of $12.86B.
Analyst price targets range from a low of $24.00 to a high of $30.00, representing a 22% spread in expectations. The median target of $26.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 15 analysts rating the stock as a Buy or Strong Buy,5 rating it Hold, and 2 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, ELAN trades at a trailing P/E of -54.8x and forward P/E of 22.7x. Analysts expect EPS to grow +387.7% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 ZTSZoetis Inc. | $33.3B | $79.40 | $84.75 | +6.7% | Hold | 12.8x | 32 |
 PCRXPacira BioSciences, Inc. | $1.4B | $36.43 | $31.60 | -13.3% | Hold | 12.6x | 36 |
 PAHCPhibro Animal Health Corporation | $1.3B | $32.96 | $28.00 | -15.0% | Buy | 10.7x | 14 |
 NEOGNeogen Corporation | $2.6B | $11.76 | $13.50 | +14.8% | Buy | 35.3x | 11 |
 PETSPetMed Express, Inc. | $26M | $1.22 | — | — | — | — | — |
 CHWYChewy, Inc. | $9.3B | $22.56 | $28.85 | +27.9% | Buy | 29.1x | 39 |
 ANIPANI Pharmaceuticals, Inc. | $1.5B | $67.41 | $99.50 | +47.6% | Buy | 7.3x | 10 |
 LLYEli Lilly and Company | $1.3T | $1354.00 | $1445.12 | +6.7% | Buy | 38.3x | 46 |
 PFEPfizer Inc. | $167.5B | $29.39 | $31.13 | +5.9% | Hold | 9.8x | 40 |
 MRKMerck & Co., Inc. | $362.3B | $146.71 | $160.47 | +9.4% | Buy | 53.0x | 38 |
Quick answers to the most common questions about buying ELAN stock.
The consensus price target for ELAN is $26.67, close to the current price of $25.74 (3.6% implied move). Based on 22 analyst estimates, the stock appears fairly valued near current levels.
ELAN has a consensus rating of "Buy" based on 22 Wall Street analysts. The rating breakdown is predominantly bullish, with 15 Buy/Strong Buy ratings. The consensus 12-month price target of $26.67 implies 3.6% upside from current levels.
ELAN trades at a forward P/E of 22.7385x, representing a moderate valuation. With analysts targeting $26.67 (3.6% implied move), the stock appears close to fair value.
The most bullish Wall Street analyst has a price target of $30 for ELAN, while the most conservative target is $24. The consensus of $26.67 represents the median expectation. These targets typically reflect 12-month expectations.
ELAN is well covered by analysts, with 22 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 15 have Buy ratings, 5 recommend Hold, and 2 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month ELAN stock forecast based on 22 Wall Street analysts shows a consensus price target of $26.67, with estimates ranging from $24 (bear case) to $30 (bull case). The median consensus rating is "Buy".
ELAN trades at a forward P/E ratio of 22.7x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
ELAN appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $26.67 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
ELAN analyst price targets range from $24 to $30, a 22% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $26.67 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.